Boehringer Ingelheim (BI) and Salipro Biotech have entered into a partnership aimed at accelerating the development of ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

Brainomix entered the US market in 2023 having gained several FDA clearances for modules within its stroke care platform.

Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched ...

Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s ...

Of the 103 patients who completed the Phase III trial, more than half witnessed remission from a drug-induced condition that ...

The One Medicine Platform replaces 20+ legacy platforms—unifying medicinal development processes & data sources into a ...

Cognizant, as the prime system integrator, began the Boehringer Ingelheim project by codeveloping a program roadmap, agile methodology, and implementation workflow. The overall scope of the ...

The partnership brings together Salipro’s tech for stabilising drug targets from Boehringer’s drug discovery programmes.

Cognizant (Nasdaq: CTSH) and Boehringer Ingelheim announced today the go-live of an end-to-end technology platform powered by ...